Acacia Research Corporation (Nasdaq:ACTG) announced today that a
subsidiary has acquired patents for catheter insertion technology.
“Acacia continues to grow its base of future revenues by adding new
patent portfolios”
"Acacia continues to grow its base of future revenues by adding new
patent portfolios,” commented Paul Ryan, Acacia Chairman and CEO. “As
our licensing success grows, more patent owners are selecting us as
their partner for the licensing of their patented technologies,”
concluded Mr. Ryan.
The patented technology generally relates to catheterization of patients
using a guide wire and a flushing port. The technology can be used to
facilitate insertion of catheters for intravenous treatments such as
chemotherapy for cancer, drug therapy for pain mitigation or antibiotic
therapy for infections.
Patient-derived organoids: Transforming cancer research and personalized medicine